Defined as having a corrected calcium level greater than 2.65mmol/L
Aetiology
Hypercalcemia of malignancy occurs in approximately 20% of all cancer patients during their clinical course
The most common cancer associated with hypercalcemia is multiple myeloma
Pathophysiology
The pathophysiology of hypercalcemia of malignancy is explained mainly through three mechanisms: excessive secretion of parathyroid hormone-related protein (PTHrP), bony metastases with the release of osteoclast activating factors, or the production of 1,25-dihydroxy vitamin D (calcitriol)